Martine Pergent, Johan Prevot and Leire Solis attended the SCIDNET and RECOMB meetings organized from 8 to 10 April 2019 in Leiden (the Netherlands).
The meetings, organised by the two research projects, brought together more than 50 participants representing most of the partners involved in the consortia to discuss the progress made by the different work groups, assess the timelines set in the proposal and jointly discuss the challenges and potential solutions encountered since the last meetings.
IPOPI was invited to participate as a partner into the projects to bring in the voice of the patients with primary immunodeficiencies into the research and development process of these highly innovative therapies for SCID.
SCIDNET and RECOMB are 2 research projects funded by one of the research programmes the European Commission has made available to researchers in Europe (European Union’s Horizon 2020 research and innovation programme). These two exciting projects have the ambition to develop gene therapies, from the early clinical trial phases up to the licensing of the product, for specific types of SCID (SCIDNET for ADA SCID and RECOMB for RAG1-SCID).